Literature DB >> 3756694

Magnetic resonance imaging for detecting lesions of multiple sclerosis: comparison with computed tomography and clinical assessment.

L Reese, T J Carr, R L Nicholson, E K Lepp.   

Abstract

Eighty-two patients with known or suspected multiple sclerosis (MS) were examined by means of magnetic resonance imaging (MRI) with a 0.15-T resistive scanner. The diagnosis could be made by MRI in 34 (97%) of the 35 patients with chronic, well-documented, stable MS and by high-volume delayed x-ray computed tomography (HVD CT) in only 6 (54%) of 11 patients in this group. The stage of the disease as judged from the MRI scans correlated poorly with the clinical status of the patient and with the known duration of the disease. MRI identified 28 (88%) of the 32 patients in whom MS was subsequently diagnosed by a neurologist, whereas regular contrast or HVD CT identified only 11 (52%) of 21 such patients. MRI is the most sensitive imaging modality for MS but is of little value in assessing the severity of the disease: many of the lesions seen on MRI scans are clinically "silent", and MRI does not usually detect small lesions in the brainstem, cerebellum or spinal cord that may be clinically significant.

Entities:  

Mesh:

Year:  1986        PMID: 3756694      PMCID: PMC1491307     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  11 in total

1.  FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1965-07       Impact factor: 9.910

2.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 3.  Magnetic resonance imaging: present and future applications.

Authors:  D L Johnston; P Liu; G L Wismer; B R Rosen; D D Stark; P F New; R D Okada; T J Brady
Journal:  Can Med Assoc J       Date:  1985-04-01       Impact factor: 8.262

4.  New perspectives in computed tomography of multiple sclerosis.

Authors:  F V Viñuela; A J Fox; G M Debrun; T E Feasby; G C Ebers
Journal:  AJR Am J Roentgenol       Date:  1982-07       Impact factor: 3.959

5.  The initial diagnosis of multiple sclerosis: clinical impact of magnetic resonance imaging.

Authors:  S S Gebarski; T O Gabrielsen; S Gilman; J E Knake; J T Latack; A M Aisen
Journal:  Ann Neurol       Date:  1985-05       Impact factor: 10.422

6.  NMR imaging in medicine.

Authors:  I L Pykett
Journal:  Sci Am       Date:  1982-05       Impact factor: 2.142

7.  Nuclear magnetic resonance imaging of the brain in multiple sclerosis.

Authors:  I R Young; A S Hall; C A Pallis; N J Legg; G M Bydder; R E Steiner
Journal:  Lancet       Date:  1981-11-14       Impact factor: 79.321

8.  Hyperbaric oxygen therapy in chronic stable multiple sclerosis: double-blind study.

Authors:  G D Harpur; R Suke; B H Bass; M J Bass; S B Bull; L Reese; J H Noseworthy; G P Rice; G C Ebers
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

9.  Nuclear magnetic resonance imaging in multiple sclerosis.

Authors:  S A Lukes; L E Crooks; M J Aminoff; L Kaufman; H S Panitch; C Mills; D Norman
Journal:  Ann Neurol       Date:  1983-06       Impact factor: 10.422

10.  Nuclear magnetic resonance (NMR) imaging in white matter disease of the brain using spin-echo sequences.

Authors:  I R Young; C P Randell; P W Kaplan; A James; G M Bydder; R E Steiner
Journal:  J Comput Assist Tomogr       Date:  1983-04       Impact factor: 1.826

View more
  2 in total

1.  Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis.

Authors:  L Kappos; D Städt; M Ratzka; W Keil; S Schneiderbanger-Grygier; T Heitzer; S Poser; M Nadjmi
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

2.  Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis.

Authors:  Suzana Marusic; Michael W Leach; Jeffrey W Pelker; Mihai L Azoitei; Naonori Uozumi; Junqing Cui; Marina W H Shen; Charlene M DeClercq; Joy S Miyashiro; Brenda A Carito; Paresh Thakker; David L Simmons; John P Leonard; Takao Shimizu; James D Clark
Journal:  J Exp Med       Date:  2005-09-19       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.